ERBB2 and breast cancer: (2022) and his colleagues found that combination therapy with tucatinib and abemaciclib could reduce tumor growth and significantly and prolong survival time in mouse models of HER2+ BC with brain metastases, while tucatinib or abemaciclib as monotherapy did not show significant therapeutic benefit (61).